NCT02324101

Brief Summary

Detect plasma Hsp90α concentration of breast cancer patients, healthy volunteers, benign breast diseases patients

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1,100

participants targeted

Target at P75+ for not_applicable breast-cancer

Timeline
Completed

Started Apr 2013

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2013

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2014

Completed
13 days until next milestone

First Submitted

Initial submission to the registry

December 14, 2014

Completed
10 days until next milestone

First Posted

Study publicly available on registry

December 24, 2014

Completed
Last Updated

December 24, 2014

Status Verified

April 1, 2013

Enrollment Period

1.7 years

First QC Date

December 14, 2014

Last Update Submit

December 22, 2014

Conditions

Breast Cancer

Outcome Measures

Primary Outcomes (1)

  • Hsp90α Concentration(ng/ml) of plasma

    Detect Hsp90α Concentration(ng/ml) of plasma and calculate the accuracy, specificity and sensitivity of Hsp90α kit

    4 months

Study Arms (1)

Breast cancer

EXPERIMENTAL

Detect plasma Hsp90α concentration of breast cancer patients

Device: Hsp90

Interventions

Hsp90DEVICE

Detect plasma Hsp90α concentration

Also known as: Biomarker
Breast cancer

Eligibility Criteria

Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • breast cancer patients, healthy volunteers, benign breast diseases patients

You may not qualify if:

  • Patients who previously received radiotherapy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Tianjin cancer hospital

Tianjin, Tianjin Municipality, China

RECRUITING

MeSH Terms

Conditions

Breast Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Study Officials

  • Zhongsheng Tong, MD

    Tianjin cance hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Zhongsheng Tong, MD

CONTACT

022

Fei Wu, MD

CONTACT

010wufei@protgen.com

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 14, 2014

First Posted

December 24, 2014

Study Start

April 1, 2013

Primary Completion

December 1, 2014

Study Completion

December 1, 2014

Last Updated

December 24, 2014

Record last verified: 2013-04

Locations

CN(1)